Automatic Website Traffic RSS
Interferon Beta | AutoTraffic Interferon Beta Drugs for Multiple Sclerosis
Your body makes interferons naturally. Three forms -- alpha, beta, and gamma -- control the activity of your immune system. But doctors also can use a man-made ...
read more Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
The annualized relapse rate was lower with daclizumab HYP than with interferon beta-1a (0.22 vs. 0.39; 45% lower rate with daclizumab HYP; P<0.001). The number of new or newly enlarged ...
read more Dose and Frequency of Administration of Interferon-Beta Affect its Efficacy in Multiple Sclerosis
Data reviewed in this article demonstrate that both interferon-ß-1a (IFNß-1a) and interferon-ß-1b (IFNß-1b) show a dose-response relationship in multiple sclerosis at current clinical doses.
read more Navigating the maze of cancer: How precision medicine unravels the unknown
In our journey to unravel the obscurities of high-grade gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs), we've embarked on a quest guided by personalized medicine principles. Imagine you're ...
read more interferon beta-1a
This page shows the latest interferon beta-1a news and features for those working in and with pharma, biotech and healthcare. This was done to encourage HCPs to prescribe the MS drugs Avonex ...
read more How interferon beta protein treatment helps fight coronavirus
The company's CEO, Richard Marsden, explained how the treatment uses a protein called interferon beta, which our bodies produce to help fight viral infections. The results have not been published ...
read more Multiple Sclerosis : What Is It & Treatments
Overview A disease that affects central nervous system. The immune system attacks the myelin, the protective layer around nerve fibers and causes Inflammation and lesions. This makes it difficult for ...
read more Global Interferons Market Poised for Remarkable Growth, Reaching US$ 13.8 Billion by 2032
The global interferons market is set to embark on a remarkable growth trajectory, with a projected valuation of US$ 13.8 billion by the conclusion of 2032. This revelation stems from the latest ...
read more Ozanimod Controls MS Disease Activity Regardless of Age
Ozanimod was approved to treat RMS in 2020 based on data from the pivotal SUNBEAM and RADIANCE studies, which showed lower relapse rates with ozanimod compared with interferon beta-1a. Patients ...
read more Room-temperature Storage of Medications Labeled for Refrigeration
Diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant) and inactivated poliovirus vaccine combined Pediarix (GlaxoSmithKline) 24 hr Manufacturer Diphtheria and ...
read more Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
The primary end point was the annualized relapse rate. The annualized relapse rate was lower with daclizumab HYP than with interferon beta-1a (0.22 vs. 0.39; 45% lower rate with daclizumab HYP ...
read more Subscribe to RSS Feed